JP2019531705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531705A5 JP2019531705A5 JP2019505188A JP2019505188A JP2019531705A5 JP 2019531705 A5 JP2019531705 A5 JP 2019531705A5 JP 2019505188 A JP2019505188 A JP 2019505188A JP 2019505188 A JP2019505188 A JP 2019505188A JP 2019531705 A5 JP2019531705 A5 JP 2019531705A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- less
- mutation
- compared
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 154
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 154
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 154
- 230000035772 mutation Effects 0.000 claims description 87
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 21
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 238000000423 cell based assay Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 claims description 6
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 claims description 6
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000001393 triammonium citrate Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 4
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000008782 phagocytosis Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 230000001447 compensatory effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 230000031998 transcytosis Effects 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096036A JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370201P | 2016-08-02 | 2016-08-02 | |
| US62/370,201 | 2016-08-02 | ||
| US201762485671P | 2017-04-14 | 2017-04-14 | |
| US62/485,671 | 2017-04-14 | ||
| PCT/US2017/045126 WO2018052556A1 (en) | 2016-08-02 | 2017-08-02 | Engineered polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096036A Division JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531705A JP2019531705A (ja) | 2019-11-07 |
| JP2019531705A5 true JP2019531705A5 (enExample) | 2020-09-10 |
| JP7464389B2 JP7464389B2 (ja) | 2024-04-09 |
Family
ID=59656189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505188A Active JP7464389B2 (ja) | 2016-08-02 | 2017-08-02 | 操作されたポリペプチドおよびその使用 |
| JP2022096036A Withdrawn JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096036A Withdrawn JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11858980B2 (enExample) |
| EP (1) | EP3494134B1 (enExample) |
| JP (2) | JP7464389B2 (enExample) |
| KR (2) | KR102777127B1 (enExample) |
| CN (3) | CN110072887A (enExample) |
| AU (2) | AU2017325654B2 (enExample) |
| BR (1) | BR112019001989A2 (enExample) |
| CA (1) | CA3032820A1 (enExample) |
| CL (3) | CL2019000261A1 (enExample) |
| CO (1) | CO2019000931A2 (enExample) |
| IL (2) | IL315729A (enExample) |
| MX (1) | MX2019001458A (enExample) |
| SG (1) | SG11201900616UA (enExample) |
| WO (1) | WO2018052556A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013540757A (ja) | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| KR102777127B1 (ko) | 2016-08-02 | 2025-03-07 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| CN109863170B (zh) | 2016-08-12 | 2024-08-16 | 詹森生物科技公司 | 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子 |
| SG11201900744SA (en) * | 2016-08-12 | 2019-02-27 | Janssen Biotech Inc | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| WO2018144991A1 (en) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| KR102748986B1 (ko) * | 2018-01-26 | 2025-01-02 | 젠자임 코포레이션 | FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체 |
| SG11202007815TA (en) * | 2018-03-05 | 2020-09-29 | Oncoimmune Inc | Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids) |
| US20190307885A1 (en) | 2018-04-04 | 2019-10-10 | Alivio Therapeutics, Inc. | Self-assembled gels for controlled delivery of biologics and methods of making thereof |
| JP7372237B2 (ja) * | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
| EP3847650A1 (en) | 2018-09-06 | 2021-07-14 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| PE20211867A1 (es) * | 2018-11-01 | 2021-09-21 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpos biespecificos y su uso |
| EP3883968A4 (en) * | 2018-11-22 | 2022-08-17 | Agency for Science, Technology and Research | MODIFIED FC REGION |
| EP3902836A4 (en) | 2018-12-18 | 2022-08-31 | Boehringer Ingelheim IO Canada Inc. | FLT3 AGONISTIC ANTIBODIES AND THEIR USES |
| JP2022514290A (ja) * | 2018-12-20 | 2022-02-10 | ジェネンテック， インコーポレイテッド | 改変抗体ｆｃおよび使用方法 |
| US20220251173A1 (en) * | 2019-05-23 | 2022-08-11 | Xiamen University | Anti-hepatitis b virus antibodies and use thereof |
| US12338291B2 (en) | 2019-06-17 | 2025-06-24 | Visterra, Inc. | Humanized antibody molecules to CD138 and uses thereof |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CN114423782A (zh) * | 2019-09-04 | 2022-04-29 | 西达赛奈医疗中心 | 不含钙调磷酸酶抑制剂的ctla4-ig+抗il6/il6r用于对实体器官移植受体进行长期免疫抑制的用途 |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| EP4073107A1 (en) | 2019-12-11 | 2022-10-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN111254207A (zh) * | 2020-01-22 | 2020-06-09 | 郑州大学第一附属医院 | 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用 |
| JP2023531722A (ja) | 2020-06-24 | 2023-07-25 | ビステラ， インコーポレイテッド | Ａｐｒｉｌに対する抗体分子およびその使用 |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| AU2022211021A1 (en) | 2021-01-20 | 2023-08-03 | Visterra, Inc. | Interleukin-2 mutants and uses thereof |
| WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| CA3238574A1 (en) | 2021-12-01 | 2023-06-08 | Gregory Babcock | Methods of using interleukin-2 agents |
| MX2024009868A (es) | 2022-02-11 | 2024-08-20 | Visterra Inc | Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias. |
| AU2023262513A1 (en) | 2022-04-25 | 2024-12-05 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CN115028738B (zh) * | 2022-06-14 | 2025-05-16 | 天津医科大学 | 一种Fc融合蛋白双重靶向降解剂及应用 |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| US20240150447A1 (en) * | 2022-11-04 | 2024-05-09 | Cephalon, LLC | Compositions and methods for increasing transport into the brain |
| AU2024232879A1 (en) * | 2023-03-06 | 2025-09-11 | Joint Stock Company "Biocad" | Antibody-like molecule comprising heterodimer of human cd1b (cluster of differentiation 1) protein |
| WO2024211779A1 (en) * | 2023-04-05 | 2024-10-10 | The Regents Of The University Of California | Affinity peptides for diagnosis and treatment of viral infections |
| CN120060370A (zh) * | 2023-11-29 | 2025-05-30 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025221954A1 (en) | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2491488A1 (en) | 2002-07-09 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| AU2012203476A1 (en) | 2003-11-12 | 2012-07-05 | Biogen Idec Ma Inc. | Neonatal Fc Receptor (FcRn)-Binding Polypeptide Variants, Dimeric Fc Binding Proteins and Methods Related Thereto |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006076594A2 (en) * | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| JPWO2008032833A1 (ja) | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Ａｄｃｃ活性を増強させた抗体及びその製造方法 |
| EP2087111A2 (en) | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
| ES2742268T3 (es) | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| CA2739429C (en) | 2008-10-14 | 2020-12-22 | Lisa A. Damico | Immunoglobulin variants and uses thereof |
| WO2010068722A1 (en) * | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| AU2015200990B2 (en) | 2009-03-20 | 2016-07-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| WO2011057198A1 (en) | 2009-11-09 | 2011-05-12 | Carson Cantwell G | Vaccine testing system |
| US20170039314A1 (en) | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| EP2550529B1 (en) | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| CN103429261A (zh) | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| WO2012109133A1 (en) | 2011-02-07 | 2012-08-16 | Research Development Foundation | Engineered immunoglobulin fc polypeptides |
| WO2012132067A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| DK2698431T3 (da) | 2011-03-30 | 2020-11-30 | Chugai Pharmaceutical Co Ltd | Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| CA3186128A1 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| CN110680920A (zh) | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | 诱导针对靶抗原的免疫应答的抗原结合分子 |
| EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
| JP6313712B2 (ja) * | 2011-12-21 | 2018-04-18 | アムジエン・インコーポレーテツド | 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP2812350B1 (en) * | 2012-02-11 | 2019-04-03 | F.Hoffmann-La Roche Ag | R-spondin translocations and methods using the same |
| KR102475951B1 (ko) | 2012-02-24 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자 |
| ES2746103T3 (es) | 2012-04-30 | 2020-03-04 | Medimmune Llc | Moléculas con función efectora reducida y semividas prolongadas, composiciones y usos de las mismas |
| US20150166654A1 (en) | 2012-05-30 | 2015-06-18 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| DK2857419T3 (da) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyle til eliminering af aggregerede antigener |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| JP6280300B2 (ja) | 2012-08-24 | 2018-02-14 | 中外製薬株式会社 | 脳疾患治療剤 |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| JP2016528167A (ja) | 2013-04-29 | 2016-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ヒトＦｃＲｎ結合改変抗体及び使用方法 |
| WO2015175874A2 (en) | 2014-05-16 | 2015-11-19 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| EP3155013B1 (en) * | 2014-06-12 | 2019-03-27 | F. Hoffmann-La Roche AG | Method for selecting antibodies with modified fcrn interaction |
| FR3024453B1 (fr) | 2014-08-01 | 2018-06-29 | Lab Francais Du Fractionnement | Procede de production de variants ayant un fc presentant une sialylation amelioree |
| SI3215528T1 (sl) * | 2014-11-06 | 2019-11-29 | Hoffmann La Roche | Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe |
| AU2016246695A1 (en) | 2015-04-07 | 2017-10-26 | Genentech, Inc. | Antigen binding complex having agonistic activity and methods of use |
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| US12391759B2 (en) | 2016-03-02 | 2025-08-19 | Momenta Pharmaceuticals, Inc. | Methods related to engineered Fc constructs |
| UA125378C2 (uk) | 2016-03-14 | 2022-03-02 | Універшітетет І Осло | МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn |
| WO2017181098A2 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| KR102777127B1 (ko) | 2016-08-02 | 2025-03-07 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| EP4424707A3 (en) | 2017-09-19 | 2024-11-13 | Tillotts Pharma AG | Antibody variants |
-
2017
- 2017-08-02 KR KR1020197006298A patent/KR102777127B1/ko active Active
- 2017-08-02 BR BR112019001989-8A patent/BR112019001989A2/pt unknown
- 2017-08-02 KR KR1020257006561A patent/KR20250036943A/ko active Pending
- 2017-08-02 CN CN201780059776.2A patent/CN110072887A/zh active Pending
- 2017-08-02 EP EP17754535.7A patent/EP3494134B1/en active Active
- 2017-08-02 SG SG11201900616UA patent/SG11201900616UA/en unknown
- 2017-08-02 WO PCT/US2017/045126 patent/WO2018052556A1/en not_active Ceased
- 2017-08-02 IL IL315729A patent/IL315729A/en unknown
- 2017-08-02 JP JP2019505188A patent/JP7464389B2/ja active Active
- 2017-08-02 CN CN202410254540.6A patent/CN118388638A/zh active Pending
- 2017-08-02 US US15/667,309 patent/US11858980B2/en active Active
- 2017-08-02 MX MX2019001458A patent/MX2019001458A/es unknown
- 2017-08-02 AU AU2017325654A patent/AU2017325654B2/en active Active
- 2017-08-02 CA CA3032820A patent/CA3032820A1/en active Pending
- 2017-08-02 CN CN202410254572.6A patent/CN118085091A/zh active Pending
-
2019
- 2019-01-30 CO CONC2019/0000931A patent/CO2019000931A2/es unknown
- 2019-01-31 IL IL264590A patent/IL264590B1/en unknown
- 2019-01-31 CL CL2019000261A patent/CL2019000261A1/es unknown
-
2020
- 2020-04-10 US US16/845,894 patent/US20200277358A1/en not_active Abandoned
-
2022
- 2022-01-06 CL CL2022000036A patent/CL2022000036A1/es unknown
- 2022-06-14 JP JP2022096036A patent/JP2022120132A/ja not_active Withdrawn
-
2024
- 2024-10-23 CL CL2024003234A patent/CL2024003234A1/es unknown
- 2024-12-03 AU AU2024270619A patent/AU2024270619A1/en active Pending
-
2025
- 2025-06-04 US US19/227,822 patent/US20250296982A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531705A5 (enExample) | ||
| ES3014619T3 (en) | Optimized fc variants | |
| CN104508133B (zh) | 用于产生单体和多聚体分子的方法及其用途 | |
| An et al. | IgG2m4, an engineered antibody isotype with reduced Fc function | |
| US10093714B1 (en) | Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof | |
| RU2675319C2 (ru) | РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc | |
| Monnet et al. | Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions | |
| EP3061770B1 (en) | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects | |
| CN108341868B (zh) | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 | |
| RU2016139006A (ru) | Мультимерные fc-белки | |
| CN105026430A (zh) | 工程化免疫球蛋白重链-轻链对及其用途 | |
| CN105102618A (zh) | 异源二聚化多肽 | |
| JP2021500348A (ja) | 単一特異性抗体から多重特異性抗体を生成させるための方法 | |
| JP2025098167A (ja) | Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 | |
| US20240043515A1 (en) | Heterodimer fc polypeptide | |
| AU2015200990A1 (en) | Optimized Fc variants | |
| AU2015202560B2 (en) | Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects | |
| RU2019104889A (ru) | Генно-инженерные полипептиды и их применение | |
| RU2810540C2 (ru) | РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc | |
| Jefferis | Fc Protein Engineering | |
| CN121057750A (zh) | 结合ox40l的抗体和使用方法 | |
| Jefferis | Antibody Fc: Chapter 17. Fc Protein Engineering | |
| AU2016213792A1 (en) | Optimized Fc variants |